NATURE:我国研究人员发现藻类TET同系物催化DNA修饰

2019-05-04 海北 MedSci原创

将胞嘧啶甲基化为5-甲基胞嘧啶(5mC)是在许多生物中普遍存在的DNA修饰。 已有的研究显示,10-11易位(TET)双加氧酶对5mC的连续氧化导致一系列额外的表观遗传标记,并促进哺乳动物中DNA的去甲基化。

将胞嘧啶甲基化为5-甲基胞嘧啶(5mC)是在许多生物中普遍存在的DNA修饰。 已有的研究显示,10-11易位(TET)双加氧酶对5mC的连续氧化导致一系列额外的表观遗传标记,并促进哺乳动物中DNA的去甲基化。

然而,TET同源物在其他真核生物中的酶活性和功能仍然很大程度上未被探索。

在这里,研究人员发现,绿藻Chlamydomonas reinhardtii含有5mC修饰酶(CMD1),它是TET同系物,并催化甘油基通过碳-碳键与5mC的甲基结合,产生两种立体异构体核碱基产物。

CMD1的催化活性需要Fe(II)和其结合基序His-X-Asp的完整性,其在Fe依赖性双加氧酶中是保守的。

然而,与之前描述的使用2-氧代戊二酸作为共底物的TET酶不同,CMD1使用L-抗坏血酸(维生素C)作为必需的共底物。维生素C将甘油基部分贡献至5℃,同时形成乙醛酸和CO2。

维生素C衍生的DNA修饰存在于野生型莱茵衣藻的基因组中,但在CMD1突变菌株中处于较低水平。CMD1突变细胞在暴露于高光水平期间的适应性降低。

LHCSR3是一种在高光条件下保护莱茵衣藻免受光氧化损伤的关键基因,与野生型细胞相比,在CMD1突变细胞中,其被高度甲基化和下调,导致光保护性非光化学猝灭能力降低。

因此,该研究鉴定了真核DNA碱基修饰,其由不同的TET同源物催化并且意外地衍生自维生素C,研究人员还描述了其作为潜在的表观遗传标记的作用,其可以在光合作用的调节中抵消DNA甲基化。


原始出处:

Xue JH et al. A vitamin-C-derived DNA modification catalysed by an algal TET homologue. NATURE, 2019; doi: 10.1038/s41586-019-1160-0.


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883698, encodeId=ecf618836987d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 15 15:34:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011409, encodeId=79d82011409fb, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Nov 13 10:34:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907594, encodeId=9262190e5945c, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Feb 07 02:34:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569359, encodeId=48431569359e6, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Mon May 06 02:34:00 CST 2019, time=2019-05-06, status=1, ipAttribution=)]
    2020-04-15 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883698, encodeId=ecf618836987d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 15 15:34:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011409, encodeId=79d82011409fb, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Nov 13 10:34:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907594, encodeId=9262190e5945c, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Feb 07 02:34:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569359, encodeId=48431569359e6, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Mon May 06 02:34:00 CST 2019, time=2019-05-06, status=1, ipAttribution=)]
    2019-11-13 yhy100200
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883698, encodeId=ecf618836987d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 15 15:34:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011409, encodeId=79d82011409fb, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Nov 13 10:34:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907594, encodeId=9262190e5945c, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Feb 07 02:34:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569359, encodeId=48431569359e6, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Mon May 06 02:34:00 CST 2019, time=2019-05-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883698, encodeId=ecf618836987d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 15 15:34:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011409, encodeId=79d82011409fb, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Nov 13 10:34:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907594, encodeId=9262190e5945c, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Feb 07 02:34:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569359, encodeId=48431569359e6, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Mon May 06 02:34:00 CST 2019, time=2019-05-06, status=1, ipAttribution=)]
    2019-05-06 zhangyxzsh

相关资讯

CLIN CHEM:在液体活检中进行可靠的基因表达和DNA甲基化分析的条件评估和质量控制步骤的实施

液体活检为癌症患者的预后和治疗提供了重要的信息。在这项研究中,研究人员评估了分析前条件对液体活检中基因表达和DNA甲基化分析的影响。将健康供体外周血(PB)中的MCF-7细胞加入6种不同储存条件的收集管中,检测循环肿瘤细胞(CTC)信使RNA的稳定性。以上皮细胞粘附分子阳性为基础富集CTCs,分离RNA,合成cDNA。使用RT-quantitative PCR对CK19和B2M基因表达进行定量。通

Nat Med:提前90天预估血糖变化!中美科学家发现DNA甲基化变化可以个性化预测血糖升高,有望用于其它慢病的监管

人生来具有一套独特的DNA,它编码的信息决定了我们眼睛是蓝是黑、个子是高是矮,甚至还能决定我们的部分性格。不过这些基因并非一成不变,实际上,通过给碱基加个甲基“帽子”这类方式,就能在不破坏基因本身的前提下改变基因表达。

DIABETOLOGIA:人类胎儿胎盘动脉和静脉内皮细胞由妊娠期糖尿病差异编程导致细胞特异性屏障功能改变

不利的宫内环境可导致后代的生理学的永久性变化,并成在年后易患疾病。妊娠期糖尿病(GDM)暴露与后代的代谢紊乱和心血管疾病的发展有关。表观遗传变异,包括DNA甲基化,被认为是支持胎儿编程的主要机制,假设表观遗传变异在接触GDM后胎儿胎盘内皮功能障碍中起关键作用。因此,研究人员进行了一项试验性的表观遗传学研究,以分析GDM暴露的胎儿胎盘内皮细胞中的DNA甲基化和基因表达变化。 研究人员对来自健康

Cell Death & Disease:在膀胱尿路上皮细胞癌中AID能够通过DNA甲基化调控致癌网络

膀胱癌是泌尿系统中最常见的恶性肿瘤之一,并且在转移后生存较差。激活诱导胞啶脱氨酶(AID)是一种多功能的酶,且与抗体多样性有关;另外也是一个致瘤基因,能够诱导体细胞超突变和类别转换重组(CSR)。然而,AID调控的DNA去甲基化对膀胱尿路上皮细胞癌(BUCC)的作用仍旧不清楚。最近,有研究人员评估了由AID引起的对BUCC影响情况,并利用蛋白组学方法探索了AID的基因下游网络。研究发现,包含AID

CLIN CANCER RES:阻止特异性DNA甲基化特征用于诊断甲状腺结节

由于恶性结节和良性结节之间细胞学特征的重叠,甲状腺癌常常难以诊断。从而导致许多没有癌症的患者不必要地切除了甲状腺。分子学方法虽然可以在细胞病理学诊断基础上得到一些改进,常常无法为甲状腺结节提供正确的诊断。这些方法的基础是癌症和周围正常甲状腺组织之间存在差异,并假设邻近组织与良性结节相同。然而,与周围正常组织相比,良性甲状腺结节可能包含可在癌症中发现的遗传改变。CLIN CANCER RES近期发表

Int J Pediatr Otorhinolaryngol:季节性过敏性鼻炎中,DNA甲基化模式鉴定

最近,有研究人员鉴定了季节过敏性鼻炎中,明显的DNA甲基化模式。研究人员从ArrayExpress数据库中获得了E-GEOD-5022的甲基化概况,并根据甲基化数据对差异共甲基化网络(DCN)进行了构建。从DCN中,研究人员鉴定了多重差异化的模式(M-DMs)。研究人员还将明显的模式定位到具体的途径中,从而鉴定富集的途径。最后,研究人员指出,在DCN中,共鉴定了16个种子基因,并利用这16个种子基